携带BRCA1或BRCA2致病性变异的女性乳腺癌后卵巢癌风险
研究随访2084例BRCA1/2携带者乳腺癌患者,15年累积卵巢癌风险BRCA1为14.9%、BRCA2为5.1%;匹配分析显示有乳腺癌史者15年累积风险10.8%低于无乳腺癌者的25.9%。结论认为BRCA相关乳腺癌女性卵巢癌风险仍高,强烈推荐行降低风险的输卵管卵巢切除术。
要点
- BRCA1携带者乳腺癌后15年累积卵巢癌风险为14.9%,BRCA2携带者为5.1%。
- 有乳腺癌史者15年累积卵巢/输卵管癌风险10.8%,低于无乳腺癌者的25.9%。
- BRCA1携带者有乳腺癌史者风险12.2%,低于无乳腺癌者的32.0%。
核心结论
- BRCA1/2携带者乳腺癌诊断后卵巢癌风险仍高,BRCA1携带者风险低于无乳腺癌者,但BRCA1和BRCA2携带者卵巢癌风险均升高。
- 考虑到卵巢癌预后差,对BRCA相关乳腺癌女性强烈推荐行降低风险的输卵管卵巢切除术。
研究设计与样本
- 研究对携带BRCA1或BRCA2突变的女性在乳腺癌诊断后进行随访,每两年完成随访问卷。
- 共纳入2084例BRCA携带者乳腺癌患者,其中BRCA1 1515例、BRCA2 569例。
- 采用匹配对照设计,纳入1378对匹配女性,比较有乳腺癌史与无乳腺癌史者的15年累积卵巢癌风险。
主要发现
- 平均随访3.9年期间,共诊断71例卵巢/输卵管癌,其中BRCA1 66例、BRCA2 5例。
- 15年累积卵巢癌风险在BRCA1携带者为14.9%,在BRCA2携带者为5.1%。
- 匹配分析中,有乳腺癌史者15年累积卵巢/输卵管癌风险为10.8%,无乳腺癌史者为25.9%。
- BRCA1携带者中,有乳腺癌史者15年风险为12.2%,无乳腺癌史者为32.0%。
- BRCA2携带者中,有乳腺癌史与无乳腺癌史者的15年卵巢癌风险均为2.0%。
临床怎么用
- 作者结论认为,对BRCA相关乳腺癌女性强烈推荐行降低风险的输卵管卵巢切除术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Inherited BRCA1/2 pathogenic variants (mutations) confer high lifetime risks of breast and ovarian cancers. Estimating the cumulative ovarian cancer risk following a breast cancer diagnosis in these women will help guide decisions regarding preventive salpingo-oophorectomy. METHODS: Women carrying a BRCA1 or BRCA2 mutation were followed after breast cancer and completed follow-up questionnaires every two years. The 15-year cumulative risk of ovarian cancer was estimated for women with a prior history of breast cancer and for matched control women without breast cancer. RESULTS: A total of 2084 BRCA carriers with breast cancer (1515 BRCA1, 569 BRCA2) were included. During a mean follow-up of 3.9 years, 71 ovarian/fallopian carcinomas were diagnosed (66 BRCA1, 5 BRCA2). The 15-year cumulative ovarian cancer risk was 14.9 % in BRCA1 and 5.1 % in BRCA2 carriers. Women with breast cancer were compared to those without; 1378 matched pairs were included. The 15-year cumulative risk of ovarian/fallopian cancer was 10.8 % in women with a history of breast cancer versus 25.9 % in those without. Among BRCA1 carriers, the risk was 12.2 % in women with breast cancer and 32.0 % in those without. Among BRCA2 carriers, the 15-year ovarian cancer risk was 2.0 % in both groups. CONCLUSIONS: Ovarian cancer risk remains high in BRCA1/2 carriers following breast cancer diagnosis. For BRCA1 mutation carriers, the risk is lower than in women without breast cancer. However, for both BRCA1 and BRCA2 the ovarian cancer risk is elevated, and considering the poor prognosis associated with ovarian cancer, risk-reducing salpingo-oophorectomy is strongly recommended for women with BRCA-associated breast cancer.
引用
- Apostol AI, Kotsopoulos J, Gronwald J, et al. Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant. Gynecol Oncol. 2025. PMID: 40784323. doi:10.1016/j.ygyno.2025.07.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。